leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharma updates on ArtemiC coronavirus study and first-ever THC shipment to Brazil

MGC Pharmaceuticals Ltd's (ASX:MXC) Roby Zomer speaks to Proactive's Andrew Scott soon after announcing positive results from a pre-clinical study of ArtemiCTM on rats with no pathological changes or differences between the study groups reported. He also discusses its first-ever shipments of the Mercury Pharma line, which includes high THC products, directly to patients in Brazil through a binding supply and distribution agreement with ONIX Empreendimentos e Participações.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.022 AUD

ASX:MXC
Market: ASX
Market Cap: $36.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharma 'confident' following completion of ArtemiC Phase II COVID-19 trial

MGC Pharmaceuticals Ltd's (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer caught up with Proactive's Andrew Scott following completion of its 50-patient Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment, ArtemiC, on patients diagnosed with COVID-19. Final...

2 weeks, 2 days ago

2 min read